FDA has modified the dosage regimen for nivolumab (Opdivo), sponsored by Bristol-Myers Squibb Co., for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. The currently approved recommended dosage regimens were modified to 240 mg intravenously (IV) every two weeks. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p...
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
